(Reuters) – The European Union’s medicines regulator said on Thursday it has started a real-time review of AstraZeneca’s antibody-based COVID-19 therapy after the combination medicine showed success in treating and preventing severe illness.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)
